Evolus Inc (EOLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evolus Inc (EOLS) has a cash flow conversion efficiency ratio of 0.116x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.59 Million) by net assets ($-30.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EOLS stock market capitalisation for the company's overall valuation and market capitalisation.
Evolus Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Evolus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EOLS stock price and chart for real-time trading data and today's change.
Evolus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evolus Inc ranked by their cash flow conversion efficiency. Review cash generation quality of Evolus Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai HiTech Control System
SHE:002184
|
-0.100x |
|
YoungPoong
KO:000670
|
0.076x |
|
Anshan Senyuan Road Bridge
SHE:300210
|
0.026x |
|
Carriage Services Inc
NYSE:CSV
|
0.027x |
|
Chongqing VDL Electronics Co. Ltd. A
SHE:301121
|
-0.019x |
|
Shanghai Join Buy Co Ltd
SHG:600838
|
0.003x |
|
WashTec AG
XETRA:WSU
|
0.143x |
|
Ningbo Jianan Electronics Co Ltd
SHE:300880
|
0.076x |
Annual Cash Flow Conversion Efficiency for Evolus Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Evolus Inc from 2015 to 2025. Also see total assets of Evolus Inc for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-23.11 Million | $-42.27 Million | 1.829x | +156.12% |
| 2024-12-31 | $5.52 Million | $-18.00 Million | -3.260x | -298.29% |
| 2023-12-31 | $-20.69 Million | $-34.01 Million | 1.644x | +135.81% |
| 2022-12-31 | $18.50 Million | $-84.91 Million | -4.590x | -1025.61% |
| 2021-12-31 | $81.88 Million | $-33.39 Million | -0.408x | -151.41% |
| 2020-12-31 | $-72.96 Million | $-57.87 Million | 0.793x | +167.49% |
| 2019-12-31 | $79.46 Million | $-93.38 Million | -1.175x | -286.39% |
| 2018-12-31 | $84.38 Million | $-25.67 Million | -0.304x | -276.28% |
| 2017-12-31 | $-75.54 Million | $-13.04 Million | 0.173x | -90.76% |
| 2016-12-31 | $-7.11 Million | $-13.27 Million | 1.867x | +161.59% |
| 2015-12-31 | $12.00 Million | $-36.38 Million | -3.031x | -- |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels,… Read more